Xencor (NASDAQ:XNCR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Several other equities analysts have also recently commented on XNCR. BidaskClub raised shares of Xencor from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $40.00 price objective on shares of Xencor in a research note on Tuesday, November 6th. Canaccord Genuity boosted their price objective on shares of Xencor from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. BTIG Research assumed coverage on shares of Xencor in a research note on Monday, September 10th. They set a “buy” rating and a $56.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Xencor in a research note on Monday, October 8th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Xencor has an average rating of “Buy” and an average price target of $41.57.

Shares of XNCR stock opened at $39.41 on Tuesday. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -37.53 and a beta of 1.79. Xencor has a 52 week low of $19.89 and a 52 week high of $48.38.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.57. The company had revenue of $29.04 million during the quarter. On average, equities analysts forecast that Xencor will post -1.53 EPS for the current year.

In other Xencor news, insider Paul A. Foster sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $46.03, for a total value of $1,841,200.00. Following the completion of the transaction, the insider now owns 44,952 shares of the company’s stock, valued at approximately $2,069,140.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder John S. Stafford III sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $48.05, for a total transaction of $48,050.00. The disclosure for this sale can be found here. 4.70% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in shares of Xencor in the 3rd quarter worth approximately $142,000. Sei Investments Co. bought a new stake in Xencor during the 2nd quarter valued at $138,000. Public Employees Retirement Association of Colorado raised its holdings in Xencor by 64.7% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 4,404 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,730 shares during the last quarter. UBS Group AG raised its holdings in Xencor by 449.9% during the 1st quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 4,886 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Xencor during the 2nd quarter valued at $232,000. Hedge funds and other institutional investors own 82.17% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Different Types of Derivatives

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.